drugset / Trial / NCT03468543

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

NCT03468543

Phase 0 Terminated 3 enrolled Lyndra Inc.
Non-randomizedSequentialOpen-labelBasic science

Summary

To assess how long modified release (MR) memantine hydrochloride prototype capsule formulations stay in the stomach as determined by magnetic resonance imaging (MRI).

Timeline

Start
2017-07-26
Primary completion
2017-09-18
Completion
2017-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 50 mg Oral

Indications